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Abstract: Antimicrobial resistance (AMR) is a major concern facing global health today, with the
greatest impact in developing countries where the burden of infectious diseases is much higher.
The inappropriate prescribing and use of antibiotics are contributory factors to increasing antibiotic
resistance. Antimicrobial stewardship programmes (AMS) are implemented to optimise use and
promote behavioural change in the use of antimicrobials. AMS programmes have been widely
employed and proven to improve antibiotic use in many high-income settings. However, strategies
to contain antimicrobial resistance have yet to be successfully implemented in low-resource settings.
A recent toolkit for AMS in low- and middle-income countries by the World Health Organisation
(WHO) recognizes the importance of local context in the development of AMS programmes. This
study employed a bottom-up approach to identify important local determinants of antimicrobial
prescribing practices in a low-middle income setting, to inform the development of a local AMS
programme. Analysis of prescribing practices and interviews with prescribers highlighted priorities
for AMS, which include increasing awareness of antibiotic resistance, development and maintenance
of guidelines for antibiotic use, monitoring and surveillance of antibiotic use, ensuring the quality
of low-cost generic medicines, and improved laboratory services. The application of an established
theoretical model for behaviour change guided the development of specific proposals for AMS. Finally,
in a consultation with stakeholders, the feasibility of the plan was explored along with strategies for
its implementation. This project provides an example of the design, and proposal for implementation
of an AMS plan to improve antibiotic use in hospitals in low-middle income settings.
Keywords: antimicrobial resistance; stewardship programmes; low and middle-income countries
1. Introduction
Rising AMR is viewed as a significant threat to global health. Concerted efforts to stem the rise in
antimicrobial resistance and to ensure effective antimicrobial therapies for future generations is seen
as a priority for the global community. Injudicious prescribing and use of antibiotics are considered
principal drivers of increasing resistance. Thus, the central focus of initiatives to address AMR is on
antimicrobial stewardship [1].
Whilst a global concern, inappropriate use of antibiotics and consequent problems of antimicrobial
resistance are greater in low- and middle-income settings [2]. The determinants of antibiotic prescribing
practices in resource-poor settings have been found to be wide-ranging [3]. Studies with health
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professionals have identified a poor appreciation of core principles, knowledge of antibiotic prescribing
and problems of resistance, refs. [4–6] limited continuing medical education, ref. [7] a lack of updated
policies and treatment guidelines, ref. [8] quality of antimicrobial medicines [9] and selective pressures
from pharmaceutical companies [10]. There is commonly limited availability of expertise and diagnostic
facilities to guide the choice of antibiotics [11,12].
Despite expansion of health insurance schemes, for many citizens, there is still no reliable funding
stream to pay for care: consultation, diagnostic tests, and treatment. Dependence of many patients on
out-of-pocket payments can affect prescribing decisions of prescribers and result in inappropriate and
unregulated self-medication with antibiotics by patients [13,14]. To be effective, AMS strategies and
interventions must be comprehensive, taking into account the different sectors in which antibiotics are
used, promoting general hygiene, access to clean water, and public health measures. However, actions
are required at all levels and this project focused on antibiotic prescribing in hospitals [3].
Suboptimal antibiotic prescribing practices remain common in many hospitals in low and
middle-income countries (LMICs), and have been linked to increased incidence of antibiotic-resistant
bacteria such as Methicillin-Resistant Staphylococcus Aureus (MRSA) [15]. Typical features of prescribing
in LMICs include high volumes of antibiotic prescribing [16], although these higher levels can be
partially linked to greater burden of infectious diseases [17]. Prescribing in LMICs has also been
characterized by high empirical use of broad-spectrum antibiotics [8,18,19], non-availability of and/or
poor compliance with treatment guidelines [20] and limited use of diagnostic tests [21].
Studies conducted in high-income countries have shown how antibiotic stewardship programmes
can improve antibiotic prescribing in hospital settings, but these interventions have been poorly
employed in LMICs [22] with only limited guidance regarding how this might be operationalized, in
these settings [23]. The WHO practical toolkit for implementing AMS in LMICs provides guidance
regarding strategies and procedures, also highlights the importance of exploring local context, priorities,
and opportunities in the development of AMS programmes in LMICs [1]. In the development of a
national strategic plan to address AMR in Thailand, participation of relevant stakeholders conferred
pertinence to national and local priorities and challenges as well and stakeholders’ ownership to
champion implementation [3]. Earlier AMS strategies to improve antibiotics use in LMICs include
institutional policies, restrictions, and controlled usage using antibiotic charts [22,24]. A systematic
review found that antibiotics stewardship programmes in LMICs had some positive impact on
antibiotics use however studying the local context and adapting interventions will have more beneficial
outcomes [23].
Engagement and consultation with local stakeholders will facilitate the identification of challenges
and opportunities, enabling the development of an AMS programme that is likely to be effective in
their local context [24,25]. This article reports the findings of a project, which employed a ‘bottom-up’
approach to identify important local determinants of antimicrobial prescribing practices and propose
an AMS strategy and programme that would be pertinent and feasible in hospitals in a low-income
setting leading to improvements in antibiotic prescribing practices.
2. Methods
2.1. Study Setting
This project was conducted in collaboration with hospitals in Bayelsa state, located in the Niger
Delta Region of Nigeria. Data collection for this study was conducted from July 2015 to September
2017. Nigeria is classified as a developing nation in lower/middle income group [26]. In terms of life
expectancy, maternal and child mortality and infectious disease burden, the situation in Nigeria is
typical of other LMICs. Also, as for similar countries, resources for healthcare budgets are low (in
Nigeria, less than 5% of the annual national budget is allocated for health) which is reflected in health
service provision across the different units in the public healthcare sector [27].
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2.2. Study Design
We employed a bottom-up mixed methods approach for this study. This involves distinct phases
with different methods that are interlinked to explore and provide in-depth understanding of the
subject. Antibiotic prescribing data was retrieved quantitatively and followed up with stakeholder
interviews. The project was conducted in three stages. The first stage comprised a survey of antibiotic
use across the selected study sites to establish the extent to which practices are typical of LMIC settings
and a series of interviews with prescribers recruited across all hospitals, to identify important drivers
of day-to-day prescribing practices as well as suggestions for interventions to improve antibiotic use.
Stage 2 involved the application of an established theoretical model for behavioural change along with
findings from stage 1, to develop a draft AMS strategy and plan. Stage 3 of the project comprised
consultation with purposively selected stakeholders (a range of policymakers and health professionals
with differing roles) to refine the proposals and inform an implementation plan.
2.3. Data Collection
A simple data collection tool (supplemental file 1) was developed to retrieve antibiotic prescribing
data. Antibiotic prescribing data were obtained retrospectively from patients’ case notes selected by a
simple randomized sampling. The patient appointment diaries in the medical records office was used
to identify the case notes to be retrieved. The diary held a record of patients reporting to the hospital,
the date of visit, department or unit patient was seen, the reason for the visit, diagnosis, and drugs
prescribed. From the appointment diary, we compiled a list of case note numbers belonging to patients
seen in the hospital between July and December 2015 who received one or more antibiotic prescriptions.
Prescribing data collected was imported into IBM statistical package for social sciences (SPSS) version 22
and analysed using basic descriptive frequencies. Prescribers in the study hospitals were purposively
selected to include diversity in terms of prescriber characteristics and setting. Participants were
recruited from two tertiary (university teaching hospital and federal medical centre) and two secondary
care hospitals (from mainland and island local government areas). Thus, together they provided
coverage of tertiary and secondary, and smaller and larger institutions, urban and rural, and mainland
and island settings across different levels of seniority. Prescribers details were obtained from the
medical directory which contains a list of all medical doctors and dentists practicing in the region
alongside their current practice facility, year of qualification and contact information. An information/
invitation letter (supplemental file 2) was developed and sent out to prescribers. Prescribers indicating
interest to participate in the studies were provided a consent form (supplemental file 3) to sign just
before the interviews. Participants were informed that all data will be anonymized prior to publication.
All interviews were audio recorded and transcribed verbatim. Ethical approval was applied for and
obtained from the ethical review committees of both tertiary hospitals and from the Bayelsa state
management board prior to data collection (supplemental file 4).
3. Results
Stage 1: Antibiotics prescribing practices and determinants
3.1. Survey of Antibiotic Use in Hospitals in Bayelsa State, Nigeria
Across the four study sites, data relating to 809 patients prescribed one or more antibiotics were
analysed. This comprised 264 (33%) and 246 (30%) from the two tertiary sites and 151 (19%) and 148
(18%) from the secondary care sites. More than half of the patients (53%) receiving antibiotics were
≤16 years old, and a further 21% aged 17–29 years. In 219 (27%) cases more than one different antibiotic
was prescribed. The five most commonly prescribed antibiotics, making up 75% of prescriptions
were broad-spectrum antibiotics including metronidazole, amoxicillin, amoxicillin and clavulanic acid,
cefuroxime and ciprofloxacin suggesting a high rate of empirical prescribing. The majority (58%) of
antibiotics were prescribed by brand, rather than generic name. Relevant laboratory tests such as
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microbial, culture and sensitivity tests to guide antibiotic treatment decisions were employed in only
15% of cases. In some cases where antibiotics were prescribed, tests such as abdominal scans and
fasting blood sugar were carried out and did the presence of a bacterial infection was not indicated.
There was limited observance (33% cases) of Nigerian Standard treatment Guidelines [28].
3.2. Interviews with Prescribers
To examine rationale for antibiotic prescribing in the local setting, interviews were conducted with
17 physicians (Table 1). Interviewees were purposively selected to include a diversity of physicians
from across the 4 hospitals who prescribe antibiotics in their practice. The sample include male
and female prescribers, with a spread from less than 5years up to more than 16 years in practice,
different levels of seniority and specialty; and included an infection control lead and a medical director.
Interview guides included predominantly open questions and principles of qualitative enquiry to
explore antibiotic prescribing behaviours identified in stage 1. An initial coding frame was devised to
enable a themed approach; constant comparison techniques were employed to facilitate more detailed
analysis and explanation.
Table 1. Characteristics of participants.
Characteristics Number of Participants n = 17 (%)
Gender
Male 12(70)
Female 5 (30)
years of
practice
≤5 7 (40)
6–10 4 (24)
11–15 4 (24)
≥16 2 (12)
Rank
Medical officer 7 (40)
Senior medical officer 3(18)
Principal medical officer 4 (24)
Consultant 3 (18)
Specialty
Internal Medicine 6 (35)
Paediatrics 5 (30)
Surgery 3 (18)
Obstetrics & Gynaecology 2 (12)
Level of care
Tertiary 11(65)
Secondary 6 (35)
Responses of participants revealed an awareness of, and concern about, suboptimal prescribing of
antibiotics in the study settings, as found in stage 1. In their explanations of current practices, they
highlighted high level system factors, local conditions, individual perceptions and practices all as
potential determinants of antimicrobial use. These included, a lack of system support in local settings,
especially inadequate laboratory services, excessive workload in the clinics; costs of drugs, especially in
the light of patient socioeconomic status and prevalence of out-of-pocket payments; specific demands
from patients, lack of availability of products, and shortcomings in training and knowledge and reliance
on long-term prescribing habits, impact of pharmaceutical companies’ marketing and incentives.
Respondents, notably, expressed regret that practices were often suboptimal, but saw the challenges
as complex and often beyond their control. For example, whilst interviewees displayed positive views
to the use of policies and guidelines, these were reported as being unavailable, out-of-date or difficult to
comply with because of other system factors such as non-availability of drugs. Poor laboratory services,
especially facilities that were non-functional, unstaffed and or open only for limited or irregular hours
resulted in poor availability of diagnostic services and delays in obtaining results of sensitivity tests.
This was seen by many as contributing to high levels of empirical prescribing of broad-spectrum
antibiotics. Patients without health insurance, necessitating out-of-pocket payments, could also be a
barrier to requesting diagnostic tests.
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Thus, cost and affordability for patients were often cited by prescribers who reported compromising
in the choice of drug to cheaper alternatives to ensure some antibiotic cover. The range of
products procured and stocked in the hospitals also influenced drug choice. The negative impact of
pharmaceutical companies promoting brands and incentives for prescribing was also raised. Concerns
about quality and effectiveness of some non-branded products was also reported as a driver for
brand-name rather than generic prescribing.
Whilst, the patterns and determinants of antibiotic prescribing in these hospitals were often typical
of those reported in other LMIC settings, the observations and experiences of prescribers, facilitated
their engagement in proposing suggestions and recommendations for AMS interventions pertinent to
their settings and challenges. Prescribers identified a diversity of macro and micro-level factors as
determinants of antibiotic use and potential targets of an AMS programme. These are summarized in
Table 2.
Table 2. Domains for antimicrobial stewardship programmes (AMS) actions as identified by prescribers.
• Improve diagnostic testing and services
• Education and training for prescribers
• Enhanced local awareness campaigns and advertising
• Provide and maintain up-to-date local policy and prescribing guidelines
• Enforcement of local guidelines
• Restrictive prescribing for some antibiotics (in accordance with local guidelines)
• Regulation of Pharmaceutical Company marketing
• Conduct routine audits and local studies to inform guidelines, identify problems and monitor practice
Steps to improve the availability of drugs:
• Ensure continuous supplies (with a separate focus on local prescribing guidelines and specialist needs)
• Improve affordability for patients
• Assurances of the quality of generic products
• Enhanced role for pharmacist interventions
Stage 2: Development of an AMS plan using a framework of behaviour change
To guide the development of an AMS programme, a validated framework the Behaviour Change
Wheel (BCW) was employed [29]. Theoretical frameworks have been commonly applied to facilitate
the development of complex interventions [30,31]. The BCW was selected because it provides a
comprehensive, systematic approach incorporating high-level system factors, local context, and
individual characteristics, all of which, in stage 1, were found to be determinants of prescribing
practices in the local settings. In addition to seven policy categories (the outer wheel) the BCW also
presents a methodology for intervention on the basis of function or approach. These intervention
functions also coincided with suggestions from prescribers and could be incorporated into AMS
programmes and strategies. The inner core of the BCW focuses on behaviour change at the individual
level. It applies the concepts of capability, opportunity and motivation to examine prescribers’ roles,
experiences, and perspectives. Through the application of intervention functions, these are seen as a
central focus for behaviour change. (See Figure 1).
Using the BCW framework (policy categories and intervention functions) along with the domains
and specific suggestions of prescribers and stakeholders, a draft framework for an AMS programme
was constructed (Table 3). In this draft framework, the suggestions made by prescribers were also
identified as those that would be part of a short/immediate or longer-term strategy. This was viewed
as important, as this setting (as other LMICs) interventions are more likely to be constrained because
of limited resources and infrastructure.
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Table 3. Cont.
Policy Category InterventionFunctions
Suggestions and Recommendations from
Stages 1 and 2
Implementation
Category
Fiscal
Environmental
restructuring
Enablement
Improvements to lab facilities to provide
enabling environment for rational prescribing.
Wider coverage of health insurance,
Stocking of low-cost generics to promote
affordability for patients
Invest in quality assurance units to safeguard
product quality, so quality is not a barrier to
optimal prescribing
LT
Regulation
Training,
Restriction,
Coercion
Enablement
Implementation of prescribing guidelines
Regular auditing of practice to regulate and
inform improvements to practice
Collection and use of local data to provide
directly relevant feedback to practitioners
and teams
ST
S/MT
Legislation
Environmental
restructuring
Restriction,
Enablement
Support at Government/health policy levels
for prioritization of structural changes, and
wider enforcement.
LT
Environmental/
social planning
Environmental
restructuring
Enablement
At Government/health policy and
institutional levels: interventions as above to
ensure enabling environment
M/LT
Service provision
Education
Training
Restriction
Environmental
restructuring
Enablement
Implementation of guidelines
Availability and use of laboratory facilities
Regular auditing of practice to identify and
address problems; and ensure continued
enabling environment
MT/LT
S/M/LT
ST- Short term, MT-Medium term, LT- Long term.
Stage 3: Consultation with key stakeholders
The third stage of the project was consultation with key stakeholders. The aim of this was
to examine the feasibility and acceptability of recommendations from the perspectives of different
stakeholders and to inform a plan for implementation relevant to, and workable in, their local settings.
A purposive sample including key members of the hospital, clinical and administrative staff and
other relevant stakeholders in regulatory/policy settings were recruited. Eight participants were drawn
from different areas of practice and included a hospital medical director, prescribers, pharmacists,
microbiologist, long-standing member of Drugs and Therapeutic Committee (DTC), chairperson of the
medical association and representative from the State Ministry of Health. In this consultation, data
were collected in one to one interviews. The stakeholders expressed their views on priorities for AMS,
opportunities, and challenges for implementation in their settings.
4. Discussion
4.1. Feasibility and Priorities for Implementation
The draft framework for implementing AMS in the local settings was presented to the stakeholders
and this was largely viewed as apposite and feasible. Their top priorities for implementation include
increased awareness and education about antibiotic resistance, development, and provision of policies
and guidelines on antibiotic use, monitoring and surveillance of antibiotic use, improved laboratory
and diagnostic services and ensuring availability and quality of products.
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Some of these interventions had already been initiated, particularly in the teaching hospital in
accordance with requirements for accreditation. In relation to these priorities, stakeholders’ perspectives
regarding the opportunities and challenges in their settings and potential action plans were explored.
The findings are reported in Table 4.
Table 4. Priorities, opportunities, and barriers leading to action plan.
Increasing awareness and education about antibiotic resistance
It was recommended that initiatives to increase awareness should target patients, other health professionals as well
as prescribers.
Stakeholders perceived that there was a general awareness, and one hospital reported to have already held a
presentation. Thus, there were some opportunities to build on existing initiatives. Stakeholders saw important
challenges in addressing attitudes and behaviours. Securing engagement and attendance and promoting a desire among
practitioners to change was highlighted.
Recommendations for AMS action plan and implementation:
• Appoint high profile leader/ AMS champion to act as a focal point to encourage engagement and oversee publicity
campaigns and training
• Employ a wide-ranging approach to increasing awareness and training appropriate to all stakeholders
including patients.
Provision of policies and guidelines
Stakeholders reported that in the past prescribing guidelines had been developed, but these were commonly seen as not
up-to-date or not readily accessible.
A potential challenge in the development of guidelines was having sufficient expertise for their development. However,
it was acknowledged that a wide range of stakeholders e.g. DTC, infectious disease clinicians and scientists,
pharmacists would bring together their professional expertise.
Ensuring engagement, ownership and acceptance by all stakeholders was seen as important for co-operation,
compliance and enforcement. In one setting, restricted dispensing had already been accepted by the DTC, which
included a procedure for review and approval of restricted products. Acceptance and implementation may be facilitated
by a collaborative approach (scientists and health professionals) to their development.
• An inter-professional approach to development of policies and guidelines bringing together and enhancing local
expertise, ensuring local relevance and ownership.
• A collaborative approach to maintenance and review of guidelines and to agree oversight and co-operation in
their enforcement.
Monitoring and surveillance of antibiotic use
On-going monitoring of the use of antibiotics and local research on infections and resistance could inform more rational
use and was also of value in the development of policies and guidelines.
A monitoring or surveillance programme was also seen as a way of engaging professional groups and bringing them
together in a shared AMS programme. In one site discussions had already begun. The principal barrier identified was
having sufficient personnel with expertise to lead for an on-going surveillance and research programme. Possible action
points were:
• Develop programme for on-going monitoring which engages different professional groups
• Identify individuals and address any training needs in audit, surveillance, and research
Improved laboratory and diagnostic services
Improvement of laboratory services and training of scientists to reduce empirical prescribing was identified as a
requirement to guide judicious antibiotic prescribing. The key challenge highlighted was the recruitment of scientists
with sufficient expertise. It was suggested that pharmaceutical companies may be able to assist, e.g. with the provision
of sensitivity discs for their products. Thus, as part of an action plan:
• AMS team could identify steps that could be taken, in both short and medium term, towards the enhancement of
laboratory facilities, services and expertise.
Procurement and quality assurance
Steps to ensure continuity in availability, affordability and trust in the quality of products (especially low-cost generics)
was seen as essential for the successful operation of an AMS programme in short, medium, and longer term. Barriers to
access to quality medicines was seen as encompassing manufacturing and regulation, affordability for patients and
prescribing practices.
In terms of quality assurance, facilities, personnel, and expertise was highlighted as a challenge. Possible collaboration
between manufacturing and regulatory bodies was also mentioned. Despite the challenges, it was viewed that the AMS
team should:
• Identify potential opportunities to improve procedures for quality assurance, availability, and affordability
of products
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4.2. Set up and Operation of the AMS Plan
The proposed AMS plan encompasses the policy categories, intervention functions and sources of
behaviour change as outlined in the three layers of the BCW in that it identifies the interacting roles
of the government (in terms of wider health policy), the institutions (the hospitals) and individuals
(practices and behaviours of prescribers, healthcare providers and patients. In the short term, the focus
is on the institutional level, in particular, interventions that address the local context and initiatives
that will support and effect behaviour change in the prescribing and use of antibiotics.
In the consultations with stakeholders, there were common strategies that emerged as relevant to
the different priorities and components of the AMS plan. First and foremost is to build the AMS team.
The make-up and operation of the team should meet the needs of all elements of the AMS programme.
In the first instance, a high-profile leader should be identified to champion the programme and give
prominence and credibility to the programme and to encourage wide engagement. Involvement
across professional groups, roles, and levels of seniority will facilitate a collaborative approach in
which the perspectives and interests of all stakeholders can be represented. Thus, other members
will include staff from the medical team, pharmacy, nursing, microbiology, medical records and
hospital management/administration. The team also needs to include individuals with more specialist
expertise to guide and implement particular aspects of the programme, e.g. laboratory skills or
experience in procurement, interactions with outside policy bodies or companies. The programme will
also require the involvement of the people with experience in publicity, organization of events and
administrative skills.
A lack of sufficient specialist expertise was highlighted in relation to a number of the priority
areas, e.g. with regard to leading local surveillance and research or laboratory skills. A first step here
may be to identify existing relevant expertise across the relevant professional groups.
In some cases, there may be staff in-post who, with some additional training, would be able to
undertake some AMS activities alongside their current roles. A longer-term plan may require further
training and/or recruitment of specialist expertise.
Through regular meetings (suggested by stakeholders as monthly in the first instance and perhaps
bi-monthly once AMS activities become established) the team will be responsible for developing a
mission statement. Subgroups should be set up to take forward specific tasks and objectives set by
the wider team. A mechanism will be required for maintaining and distributing local guidelines
throughout the hospital to reach and engage relevant staff. Other activities of the AMS team will
include regular review of antibiotics use, documentation of local bacterial sensitivity patterns and
revisions of antibiotic formulary lists. The team will also plan for surveillance and auditing of practice
(prescribing, dispensing and laboratory procedures), document findings and generate appropriate
reports. These reports will be reviewed and presented to staff as part of communication and education,
highlighting good practices as well as areas requiring improvement.
5. Conclusions
The findings from this project have informed a plan for antimicrobial stewardship in a low-resource
setting. Whilst this work commenced before the publication of the WHO toolkit, it provides a road
map to developing an AMS programme in an LMIC with locally retrieved data. This project took
a bottom-up approach combined with application of a theoretical framework of behaviour change,
leading to the development of a multifaceted AMS plan. While the AMS plan developed here has been
designed to be implemented in a specific LMIC setting, early stages of the project confirmed that many
of the practices regarding antibiotic use, prescribing patterns, barriers, and opportunities for change
are similar to those in other LMICs. Therefore, the findings presented here can be implemented in
similar resource-limited settings.
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